{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:32:52Z","timestamp":1791073972467,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020908","name":"Pfizer France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02086-0","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:48:01Z","timestamp":1751446081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study"],"prefix":"10.1186","volume":"26","author":[{"given":"M.","family":"Lanteri-Minet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Casarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bretin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gugenheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Raclot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Squara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Aissani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Saighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"11","key":"2086_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","unstructured":"GBD 2016 Headache Collaborators (2018) Global, regional, and National burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol Nov 17(11):954\u2013976","journal-title":"Lancet Neurol Nov"},{"issue":"Suppl 2","key":"2086_CR2","first-page":"1","volume":"28","author":"M Lant\u00e9ri-Minet","year":"2008","unstructured":"Lant\u00e9ri-Minet M (2008) The role of general practitioners in migraine management. Cephalalgia Int J Headache Sept 28(Suppl 2):1\u20138","journal-title":"Cephalalgia Int J Headache Sept"},{"key":"2086_CR3","unstructured":"Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis - PubMed. [cit\u00e9 6 d\u00e9c 2024]. Disponible sur: https:\/\/pubmed.ncbi.nlm.nih.gov\/39293828\/"},{"issue":"10","key":"2086_CR4","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.neurol.2024.09.008","volume":"180","author":"X Moisset","year":"2024","unstructured":"Moisset X, Demarquay G, de Gaalon S, Roos C, Donnet A, Giraud P et al (2024) Migraine treatment: position paper of the French headache society. Rev Neurol (Paris) D\u00e9c 180(10):1087\u20131099","journal-title":"Rev Neurol (Paris) D\u00e9c"},{"issue":"2","key":"2086_CR5","doi-asserted-by":"publisher","first-page":"333102422114168","DOI":"10.1177\/03331024221141686","volume":"43","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L\u2019Italien G et al (2023) Efficacy of Rimegepant for the acute treatment of migraine based on Triptan treatment experience: pooled results from three phase 3 randomized clinical trials. Cephalalgia Int J Headache F\u00e9vr 43(2):3331024221141686","journal-title":"Cephalalgia Int J Headache F\u00e9vr"},{"issue":"3","key":"2086_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/head.14089","volume":"61","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M et al (2021) Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. Headache Mars 61(3):422\u2013429","journal-title":"Headache Mars"},{"issue":"9","key":"2086_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/03331024211000311","volume":"41","author":"S Hutchinson","year":"2021","unstructured":"Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY et al (2021) Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia Int J Headache Ao\u00fbt 41(9):979\u2013990","journal-title":"Cephalalgia Int J Headache Ao\u00fbt"},{"issue":"5","key":"2086_CR8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s40122-024-00626-1","volume":"13","author":"D True","year":"2024","unstructured":"True D, Mullin K, Croop R (2024) Safety of Rimegepant in adults with migraine and cardiovascular risk factors: analysis of a multicenter, Long-Term, Open-Label study. Pain Ther Oct 13(5):1203\u20131218","journal-title":"Pain Ther Oct"},{"issue":"1","key":"2086_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s10194-023-01676-0","volume":"10","author":"R Ruscheweyh","year":"2023","unstructured":"Ruscheweyh R, Gossrau G, Dresler T, Freilinger T, F\u00f6rderreuther S, Gaul C et al (2023) Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry. J Headache Pain 10(1):135","journal-title":"J Headache Pain"},{"issue":"9","key":"2086_CR10","doi-asserted-by":"publisher","first-page":"333102424127891","DOI":"10.1177\/03331024241278911","volume":"44","author":"RJ Wilcha","year":"2024","unstructured":"Wilcha RJ, Goadsby PJ (2024) Triptan non-response in a London tertiary headache centre: what can we learn? A retrospective study. Cephalalgia Int J Headache Sept 44(9):3331024241278911","journal-title":"Cephalalgia Int J Headache Sept"},{"issue":"1","key":"2086_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12890-022-02144-2","volume":"20","author":"H Joumaa","year":"2022","unstructured":"Joumaa H, Sigogne R, Maravic M, Perray L, Bourdin A, Roche N (2022) Artificial intelligence to differentiate asthma from COPD in medico-administrative databases. BMC Pulm Med 20(1):357","journal-title":"BMC Pulm Med"},{"issue":"3","key":"2086_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jbspin.2017.03.013","volume":"85","author":"M Maravic","year":"2018","unstructured":"Maravic M, Hincapie N, Pilet S, Flipo RM, Liot\u00e9 F (2018) Persistent clinical inertia in gout in 2014: an observational French longitudinal patient database study. Joint Bone Spine Mai 85(3):311\u2013315","journal-title":"Joint Bone Spine Mai"},{"issue":"10","key":"2086_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.neurol.2024.09.008","volume":"180","author":"X Moisset","year":"2024","unstructured":"Moisset X, Demarquay G, de Gaalon S, Roos C, Donnet A, Giraud P, Gu\u00e9gan-Massardier E, Lucas C, Mawet J, Valade D, Corand V, Gollion C, Moreau N, Grangeon L, Lant\u00e9ri-Minet M, Ducros A (2024) Migraine treatment: position paper of the French headache society. Rev Neurol (Paris) 180(10):1087\u20131099","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"2086_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"12","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Ulud\u00fcz D et al (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 12(1):133","journal-title":"J Headache Pain"},{"issue":"1","key":"2086_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-023-01619-9","volume":"24","author":"L Fan","year":"2023","unstructured":"Fan L, Wu Y, Wei J, Xia F, Cai Y, Zhang S et al (2023) Global, regional, and National time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019. J Headache Pain 1 Juill 24(1):79","journal-title":"J Headache Pain 1 Juill"},{"key":"2086_CR16","unstructured":"Lanteri-Minet M, Lucas C EM-Consulte. [cit\u00e9 11 d\u00e9c 2024]. Update of French migraine epidemiology: A narrative review. Disponible sur: https:\/\/www.em-consulte.com\/article\/1705153\/update-of-french-migraine-epidemiology-a-narrative"},{"issue":"5","key":"2086_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1526-4610.2006.00430.x","volume":"46","author":"C Lucas","year":"2006","unstructured":"Lucas C, G\u00e9raud G, Valade D, Chautard MH, Lant\u00e9ri-Minet M (2006) Recognition and therapeutic management of migraine in 2004, in france: results of FRAMIG 3, a French nationwide population-based survey. Headache Mai 46(5):715\u2013725","journal-title":"Headache Mai"},{"issue":"1","key":"2086_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s10194-024-01834-y","volume":"25","author":"M Lanteri-Minet","year":"2024","unstructured":"Lanteri-Minet M, Leroux E, Katsarava Z, Lipton RB, Sakai F, Matharu M et al (2024) Characterizing barriers to care in migraine: multicountry results from the chronic migraine epidemiology and Outcomes - International (CaMEO-I) study. J Headache Pain 19 Ao\u00fbt 25(1):134","journal-title":"J Headache Pain 19 Ao\u00fbt"},{"issue":"7","key":"2086_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/13696998.2019.1590841","volume":"22","author":"A Donnet","year":"2019","unstructured":"Donnet A, Emery C, Aly S, Allaf B, Cayre F, Mahieu N et al (2019) Migraine burden and costs in france: a nationwide claims database analysis of Triptan users. J Med Econ Juill 22(7):616\u2013624","journal-title":"J Med Econ Juill"},{"issue":"7","key":"2086_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/head.14327","volume":"62","author":"A Pero","year":"2022","unstructured":"Pero A, Pace A, Dhamoon MS (2022) Triptan medication use among patients with migraine with contraindications in the US. Headache Juill 62(7):883\u2013889","journal-title":"Headache Juill"},{"key":"2086_CR21","doi-asserted-by":"publisher","first-page":"215013272096368","DOI":"10.1177\/2150132720963680","volume":"11","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Shewale AS, Lipton RB, Baum SJ, Marcus SC, Silberstein SD et al (2020) Migraine patients with cardiovascular disease and contraindications: an analysis of Real-World claims data. J Prim Care Community Health 11:2150132720963680","journal-title":"J Prim Care Community Health"},{"issue":"5","key":"2086_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/head.14304","volume":"62","author":"K Zebenholzer","year":"2022","unstructured":"Zebenholzer K, Gall W, Gleiss A, Pavelic AR, W\u00f6ber C (2022) Triptans and vascular comorbidity in persons over fifty: findings from a nationwide insurance database - A cohort study. Headache Mai 62(5):604\u2013612","journal-title":"Headache Mai"},{"issue":"1","key":"2086_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-024-01770-x","volume":"25","author":"PT Tran","year":"2024","unstructured":"Tran PT, Lapeyre-Mestre M, Berangere B, Lanteri-Minet M, Palmaro A, Donnet A et al (2024) Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events. J Headache Pain 25(1):68","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02086-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02086-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02086-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:48:03Z","timestamp":1751446083000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02086-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02086-0","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients are individually informed before data collection by the practitioner that information from their medical files may be used for scientific purposes in an anonymous manner and in compliance with medical secrecy. Patients are informed in advance to allow them, if necessary, to object to the processing of their data even before they are collected by IQVIA. In addition, measures will be taken to make information publicly available regarding the implementation of these treatments. These measures will be visible on the IQVIA France website in a specific personal data section (link to the IQVIA website) and include: a general information notice (link to the General Information Notice) applicable to EMR data and an information notice specific to the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EC, OB and CC declare to have no competing interest.AC, PAS, WA, AS and HL are employees of Pfizer France.ML-M reports personal fee for advisory boards, speaker panels or investigation studies from Allergan\/Abbvie, Amgen, Astellas, ATI, BMS, Boehringer, Boston Scientific, CoLucid, Convergence, Eli Lilly, GlaxoSmithKline, Grunenthal, Eli Lilly, IPSEN, Lundbeck, Medtronic, MSD, Novartis, Orion Pharma, PerFood, Pfizer, ReckittBenckiser, Saint-Jude, Salvia BioElectronics, Sanofi-Aventis, Teva, UCB, UPSA and Zambon.MG has received speaker\/advisory board honoraria from Sanofi-Genzyme, Alexion, Pfizer and Biogen. VR has received speaker\/advisory board honoraria from Lundbeck and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}